Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GOVX

Geovax Labs Inc

Dec 13 • 04:00PM ET

2.35

Dollar change -0.05
Percentage change -2.08	%

Healthcare • Biotechnology • USA • NASD

Peers: INO NVAX VXRT ALT BNTX CVAC MOD HEPA ITRM HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.24	Insider Own	0.47%	Shs Outstand	9.44M	Perf Week	-6.75%
Market Cap	21.71M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	22.59%	Shs Float	9.39M	Perf Month	-12.96%
Income	-24.32M	PEG	-	EPS next Q	-0.77	Inst Own	4.76%	Short Float	5.11%	Perf Quarter	-13.28%
Sales	3.09M	P/S	7.03	EPS this Y	67.39%	Inst Trans	-	Short Ratio	0.29	Perf Half Y	95.83%
Book/sh	0.99	P/B	2.38	EPS next Y	75.06%	ROA	-178.10%	Short Interest	0.48M	Perf Year	-47.78%
Cash/sh	0.93	P/C	2.53	EPS next 5Y	-	ROE	-276.02%	52W Range	1.09 - 11.18	Perf YTD	-56.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	92.12%	ROI	-286.01%	52W High	-78.98%	Beta	3.32
Dividend TTM	-	Quick Ratio	4.17	Sales past 5Y	-20.34%	Gross Margin	96.90%	52W Low	115.58%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	4.17	EPS Y/Y TTM	31.46%	Oper. Margin	-792.63%	RSI (14)	46.43	Volatility	6.64% 9.90%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-787.08%	Recom	1.00	Target Price	14.60
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	80.89%	Payout	-	Rel Volume	0.14	Prev Close	2.40
Sales Surprise	108.91%	EPS Surprise	30.85%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.68M	Price	2.35
SMA20	-9.21%	SMA50	1.16%	SMA200	-3.96%	Trades		Volume	227,310	Change	-2.08%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-24	Initiated	Alliance Global Partners	Buy	$15
Jul-16-24	Initiated	ROTH MKM	Buy	$20
Nov-19-20	Initiated	Maxim Group	Buy	$8

Dec-09-24 09:00AM	GeoVax Receives Notice of Allowance For Cancer Vaccine Patent (GlobeNewswire)
Nov-26-24 09:00AM	GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference (GlobeNewswire) -10.30%
Nov-19-24 09:00AM	GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Nov-12-24 04:00PM	GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -16.92%
07:07AM	GeoVax Labs initiated with a Buy at Alliance Global Partners (TipRanks)
09:00AM	Loading…
Nov-05-24 09:00AM	GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 (GlobeNewswire)
Oct-02-24 09:00AM	GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Sep-03-24 11:54PM	GeoVax Labs, Inc. (GOVX): A Hot Penny Stock On The Move (Insider Monkey) -15.04%
09:00AM	GeoVax to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Sep-02-24 12:17PM	10 Hot Penny Stocks On the Move (Insider Monkey)
Aug-28-24 08:59PM	GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market (GlobeNewswire) -16.25%
Aug-21-24 09:00AM	Registration is Now Open for Tribe Public's Webinar Event 'Now Is Not the Time to Monkey(pox) Around' Featuring GeoVax Lab's CEO (GlobeNewswire) +47.01%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
07:45AM	Loading…
Aug-20-24 07:45AM	GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market (GlobeNewswire) -20.56%
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-19-24 05:16PM	WHO declares mpox a public health emergency as variant emerges (Yahoo Finance Video)
Aug-15-24 09:00AM	GeoVax to Present at the Emerging Growth Conference on August 21, 2024 (GlobeNewswire)
Aug-08-24 09:00AM	GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board (GlobeNewswire) +5.06%
Aug-06-24 04:00PM	GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 10:15AM	Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review (GlobeNewswire)
09:00AM	GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review (GlobeNewswire)
Jul-30-24 09:00AM	GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 (GlobeNewswire) -8.26%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 12:54PM	GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst (InvestorPlace) +5.34%
09:00AM	GeoVax to Present at the Emerging Growth Conference on July 18, 2024 (NewMediaWire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-11-24 08:30AM	GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market (NewMediaWire) -9.38%
Jul-09-24 09:00AM	GeoVax Provides First Half 2024 Business Update (NewMediaWire) -12.20%
02:23PM	Loading…
Jun-27-24 02:23PM	Why Is GeoVax (GOVX) Stock Up 110% Today? (InvestorPlace) +76.18%
09:00AM	GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA (NewMediaWire)
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -8.41%
Jun-20-24 10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
Jun-18-24 07:00AM	GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 (NewMediaWire) +71.17%
Jun-07-24 07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -6.40%
May-29-24 09:00AM	GeoVax to Present at BIO International Convention 2024 (NewMediaWire) +7.98%
May-17-24 08:00AM	GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market (NewMediaWire)
May-15-24 08:19AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:53AM	GOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024 (InvestorPlace)
May-14-24 04:00PM	GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update (NewMediaWire)
May-07-24 09:00AM	GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 (NewMediaWire)
Apr-04-24 12:30PM	GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine (GlobeNewswire)
Mar-28-24 09:00AM	GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress (GlobeNewswire) +8.11%
Mar-12-24 09:00AM	GeoVax to Present at the 36th Annual Roth Conference (GlobeNewswire)
Mar-06-24 09:00AM	GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System (GlobeNewswire)
Mar-02-24 08:45AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 04:00PM	GeoVax Reports 2023 Year-End Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 09:00AM	GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 (GlobeNewswire)
Feb-19-24 09:00AM	GeoVax to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-13-24 09:00AM	GeoVax Announces Multiple Patent Issuances and Allowances (GlobeNewswire)
Feb-06-24 09:00AM	GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster (GlobeNewswire)
Jan-29-24 09:00AM	GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement (GlobeNewswire) -8.25%
Jan-08-24 09:00AM	GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology (GlobeNewswire)
Jan-04-24 09:00AM	GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients (GlobeNewswire)
Jan-03-24 09:00AM	GeoVax Announces Issuance of Malaria Vaccine Patent (GlobeNewswire)
Dec-27-23 09:00AM	GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 (GlobeNewswire)
Dec-19-23 09:00AM	GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox (GlobeNewswire)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 04:30PM	GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress (GlobeNewswire)
Nov-29-23 09:00AM	GeoVax to Participate in Upcoming December Investor Events (GlobeNewswire)
Nov-28-23 09:00AM	GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress (GlobeNewswire)
Nov-14-23 09:00AM	Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 (GlobeNewswire)
Nov-10-23 10:24AM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:00PM	GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-31-23 09:00AM	GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-30-23 09:00AM	GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine (GlobeNewswire)
Oct-25-23 09:00AM	GeoVax to Participate in Upcoming November Investor and Industry Events (GlobeNewswire)
Oct-24-23 09:00AM	GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities (GlobeNewswire)
Oct-09-23 09:00AM	GeoVax Receives Notice of Allowance for Marburg Vaccine Patent (GlobeNewswire)
Oct-05-23 09:00AM	GeoVax Receives Notice of Allowance for HIV Vaccine Patent (GlobeNewswire) +5.54%
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.81%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 09:00AM	GeoVax to Participate in Upcoming October Investor and Industry Events (GlobeNewswire)
Sep-26-23 09:00AM	GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-20-23 09:00AM	GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference (GlobeNewswire)
Sep-19-23 09:00AM	GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients (GlobeNewswire)
Sep-12-23 09:00AM	GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-11-23 09:00AM	GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster (GlobeNewswire)
Aug-31-23 09:00AM	GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -5.02%
Aug-29-23 09:00AM	GeoVax to Present at the Emerging Growth Conference on September 6, 2023 (GlobeNewswire)
Aug-28-23 09:00AM	GeoVax Receives Notice of Allowance for Malaria Vaccine Patent (GlobeNewswire)
Aug-11-23 12:47PM	GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:00AM	GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Aug-09-23 04:00PM	GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 09:00AM	GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 (GlobeNewswire) +11.62%
Jul-24-23 09:00AM	GeoVax Announces Issuance of Ebola Vaccine Patent (GlobeNewswire)
Jul-20-23 09:00AM	GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia (GlobeNewswire)
Jul-10-23 09:00AM	GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference (GlobeNewswire)
Jun-28-23 09:00AM	GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference (GlobeNewswire)
Jun-27-23 10:15AM	GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights (GlobeNewswire)
May-31-23 09:00AM	GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates (GlobeNewswire)
May-25-23 09:00AM	GeoVax to Participate in Upcoming Industry Meetings (GlobeNewswire) -10.67%
May-24-23 04:32PM	GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results (Benzinga) +14.17%
08:00AM	GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients (GlobeNewswire)

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DODD DAVID A	President, CEO	Aug 09 '24	Buy	1.95	8,000	15,600	26,661	Aug 12 08:47 AM
DODD DAVID A	President, CEO	Feb 22 '24	Buy	2.27	8,209	18,663	18,661	Feb 22 04:41 PM
DODD DAVID A	President, CEO	Feb 21 '24	Buy	2.15	520	1,118	10,452	Feb 22 04:41 PM
Reynolds Mark	CFO	Feb 07 '24	Buy	2.77	2,000	5,540	7,213	Feb 07 04:43 PM
McKee Kelly T. Jr.	Chief Medical Officer	Dec 22 '23	Buy	0.36	6,944	2,500	35,782	Dec 26 03:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOVX

Geovax Labs Inc

Upgrade your FINVIZ experience